Lv1
30 积分 2026-07-22 加入
P-275 First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma: randomized, phase 3 KEYNOTE-177 study
2小时前
求助中
皖公网安备34019202002308
